Literature DB >> 8997272

Colchicine inhibits arachidonate release and 5-lipoxygenase action in alveolar macrophages.

M Peters-Golden1, R W McNish, J A Davis, R A Blackwood, T G Brock.   

Abstract

Although colchicine is known to inhibit leukotriene synthesis in neutrophils, its effect on other aspects of arachidonic acid (AA) metabolism as well as its mechanism of action are unknown. To address these questions, we investigated the effects of colchicine on resident rat alveolar macrophages (AM), cells that generate a variety of lipoxygenase and cyclooxygenase products after stimulation. Pretreatment of AM with 10 microM colchicine for 1 h dramatically inhibited the synthesis of all 5-lipoxygenase (5-LO) metabolites from endogenous AA in ionophore A-23187-stimulated cells. In addition, colchicine inhibited the total release of AA as well as prostanoids to a lesser extent. Similar effects were observed with the other microtubule-disruptive agents nocodazole and vinblastine, and 5-LO product formation stimulated by the particulate agonist zymosan was inhibited as well. A selective inhibitory effect of colchicine on the 5-LO pathway was demonstrated by monitoring the synthesis of 5-LO products from exogenously supplied AA. Cell-free enzyme assays showed that this effect was not through a direct inhibition of the 5-LO enzyme. Moreover, colchicine did not affect the translocation of 5-LO to the nuclear envelope. We next evaluated the effect of colchicine on the levels of the two 5-LO cofactors, ATP and Ca2+. Although colchicine did not affect ATP levels, it did abrogate the ionophore-induced increase in intracellular Ca2+ concentration; the inhibitory effect of colchicine on 5-LO metabolism in AM was partially overcome by stimulation with higher doses of A-23187. We conclude that microtubular disruption inhibits agonist-induced increase in intracellular Ca2+ concentration, with multiple consequences for AA metabolism. These include a reduction in the liberation of AA from membrane phospholipids as well as the selective inhibition of processing of AA by 5-LO.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8997272     DOI: 10.1152/ajplung.1996.271.6.L1004

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  7 in total

Review 1.  Pulmonary diseases other than asthma as potential targets for antileukotriene therapy.

Authors:  M Peters-Golden
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 2.  Update on colchicine and its mechanism of action.

Authors:  Yair Molad
Journal:  Curr Rheumatol Rep       Date:  2002-06       Impact factor: 4.592

3.  Colchicine modulates oxidative stress in serum and leucocytes from remission patients with Family Mediterranean Fever through regulation of Ca²+ release and the antioxidant system.

Authors:  Mehmet Sahin; A Cihangir Uğuz; Halil Demirkan; Mustafa Nazıroğlu
Journal:  J Membr Biol       Date:  2011-01-20       Impact factor: 1.843

4.  Long chain fatty acid (Lcfa) abnormalities in hyper Igd syndrome (Hids) and Familial Mediterranean Fever (Fmf): new insight into heritable periodic fevers.

Authors:  Anna Simon; Joost P H Drenth; Dietrich Matern; Eric S Goetzman; Elizabeth J Hager; K Michael Gibson
Journal:  Mol Genet Metab       Date:  2013-01-15       Impact factor: 4.797

5.  High-performance Thin-layer Chromatographic-densitometric Quantification and Recovery of Bioactive Compounds for Identification of Elite Chemotypes of Gloriosa superba L. Collected from Sikkim Himalayas (India).

Authors:  Ankita Misra; Pushpendra Kumar Shukla; Bhanu Kumar; Jai Chand; Poonam Kushwaha; Md Khalid; Ajay Kumar Singh Rawat; Sharad Srivastava
Journal:  Pharmacogn Mag       Date:  2017-10-11       Impact factor: 1.085

6.  Colchicine alleviates acute postoperative pain but delays wound repair in mice: roles of neutrophils and macrophages.

Authors:  Asami Sukeishi; Koichi Isami; Haruka Hiyama; Satoshi Imai; Kazuki Nagayasu; Hisashi Shirakawa; Takayuki Nakagawa; Shuji Kaneko
Journal:  Mol Pain       Date:  2017 Jan-Dec       Impact factor: 3.395

7.  Bioactive Lipids in COVID-19-Further Evidence.

Authors:  Undurti N Das
Journal:  Arch Med Res       Date:  2020-09-09       Impact factor: 2.235

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.